There is no FDA-approved tirzepatide tablet. Tirzepatide is sold only as a once-weekly subcutaneous injection under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. If you have read about a “tirzepatide pill” or “oral tirzepatide,” you are most likely seeing one of three things: a compounded preparation that is not FDA-approved, marketing for the unrelated oral semaglutide tablet Rybelsus, or coverage of Eli Lilly’s investigational oral GLP-1 small molecule called orforglipron.
Why Tirzepatide Is Currently an Injection
Tirzepatide is a 39 amino acid peptide engineered by Eli Lilly. Like other peptide drugs, including semaglutide and insulin, it is degraded by stomach acid and intestinal enzymes when swallowed in a conventional tablet. To preserve potency, the molecule must either be injected subcutaneously, where lymphatic absorption avoids first-pass digestion, or formulated with a permeation enhancer that protects the peptide and helps it cross the gut wall. The Mounjaro and Zepbound prescribing information describe the once-weekly subcutaneous injection only, with FDA-approved doses of 2.5, 5, 7.5, 10, 12.5, and 15 mg as detailed in the Mounjaro label.
The Only FDA-Approved Oral GLP-1: Rybelsus
Rybelsus is an oral semaglutide tablet from Novo Nordisk, the same active ingredient as Ozempic and Wegovy but in pill form. Approved in 2019, Rybelsus uses a permeation enhancer called salcaprozate sodium (SNAC) to allow the semaglutide molecule to be absorbed in the stomach. Per the Rybelsus prescribing information, the tablet is taken once daily on an empty stomach with no more than four ounces of plain water, then food or other medications are held for 30 minutes. Available strengths are 3, 7, and 14 mg. Rybelsus is FDA-approved only for adults with type 2 diabetes; it is not indicated for weight loss, although weight reduction is often observed as a secondary effect.
Tirzepatide vs Oral Semaglutide
| Feature | Tirzepatide (Mounjaro / Zepbound) | Oral Semaglutide (Rybelsus) |
|---|---|---|
| Form | Subcutaneous injection | Tablet |
| Frequency | Once weekly | Once daily |
| Mechanism | GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA-Approved Indications | Type 2 diabetes (Mounjaro), chronic weight management (Zepbound) | Type 2 diabetes |
| Doses | 2.5 to 15 mg | 3, 7, 14 mg |
| Food Restriction | None | Empty stomach, then wait 30 minutes |
Orforglipron: The Oral Small Molecule Lilly Is Developing
Eli Lilly’s orforglipron is a daily oral small-molecule GLP-1 receptor agonist. Unlike Rybelsus, which is a peptide protected by a permeation enhancer, orforglipron is a non-peptide small molecule, which is more stable in the gut and does not require special administration timing. In Lilly’s phase 3 ACHIEVE-1 trial in type 2 diabetes and the ATTAIN obesity program, orforglipron lowered A1C and produced double-digit percentage weight loss in many participants. Importantly, orforglipron is not tirzepatide. It is a separate molecule that targets the GLP-1 receptor only. It is not FDA-approved as of this article’s publication, and Lilly has signaled regulatory submissions are pending.
Compounded Oral Tirzepatide Claims
Some online vendors and wellness clinics market oral or sublingual tirzepatide drops, troches, or tablets. None of these products are FDA-approved. During the 2023 to 2024 tirzepatide shortage, compounding pharmacies could legally produce certain preparations under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The FDA declared the tirzepatide shortage resolved in late 2024, narrowing the legal basis for routine compounding. The agency’s policy update on GLP-1 compounders outlines the enforcement timeline. Even when compounding was permitted, the FDA cautioned that the safety, purity, and bioavailability of compounded oral peptide preparations had not been established.
Side Effects of GLP-1 Therapy
Whether you receive a peptide as an injection or as Rybelsus, the side effect profile is similar. The most common adverse reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite. Most are dose-related and improve with slow titration. Less common but serious risks include pancreatitis, gallbladder disease, acute kidney injury from dehydration, and a boxed warning for thyroid C-cell tumors based on rodent studies. GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. If you are tracking your A1C levels alongside therapy, your prescriber may also order kidney function and lipid panels at baseline.
What to Ask Your Prescriber
- Am I a candidate for an oral or injectable GLP-1 based on my diagnosis and other medications?
- Does my insurance cover Mounjaro, Zepbound, Ozempic, Wegovy, or Rybelsus?
- What dose escalation schedule will we follow, and how will we manage nausea?
- What labs do you want to check at baseline and during therapy?
- If I read about an oral tirzepatide product, how do we verify it is legitimate?
For broader context on GLP-1 therapy and other prediabetes options, see our treatment hub.
The Bottom Line
A tirzepatide tablet does not exist as an FDA-approved product. The only oral GLP-1 currently on the US market is Rybelsus, which is oral semaglutide for type 2 diabetes. Eli Lilly’s orforglipron may eventually offer a true daily oral option, but it is not tirzepatide and is not yet approved. If a clinic offers you “oral tirzepatide” today, ask for the FDA approval letter or the manufacturer label. You will not find one. Stick with FDA-approved formulations and let your prescriber guide selection and titration.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment plan.
